-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Reiterates Buy on Belite Bio, Maintains $80 Price Target

Benzinga·03/26/2025 14:22:52
Listen to the news
Benchmark analyst Bruce Jackson reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $80 price target.